The “Smarter Monopoly” Debate Is Here—and It’s About to Get Louder
For years, the pharmaceutical industry has lived under a familiar tension: innovation needs protection, but patients need access. Standard drug patents are one way to balance that equat…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Most business development teams wait for the “cliff” to arrive—then scramble to win the scramble.
But in biologics, the cliff is predictab…
Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…
Patients aren’t asking “about patents.” They’re asking, “Will I be able to afford my medicine?”
If you’ve spent any time around drug pricing conversations lately, you’ve probably noticed a pattern: the most searched questions online rarely sound like l…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Evergreen strategies aren’t new—but the playbook is getting faster, smarter, and harder to see.
For pharma teams, the real risk isn’t just that a brand files another patent. It’s that the brand files the right kind of patent—at the right time—using the…
Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/
DrugChatter: Can you recall the initial fda approval year for keytruda? Read Post »
GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The biggest misconception about AI in healthcare is that it “replaces” work. The more consequential shift is quieter: it compresses timelines, changes who …
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
In pharma, the phrase patent cliff is often treated like weather: inevitable, disruptive, and largely outside your control. But the most effective companie…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
OpenAI’s GPT just did something that should make pharma lawyers sit up: it’s being credited with “smashing” drug patent cliffs—by accelerating the work that used to take teams months (or longer) to complete.
That’s the claim behind the latest buzz from…
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
According to the manufacturer’s information on DrugPatentWatch.com [1], Vascepa (icosapent ethyl) is an omega-3 fatty… https://www.Drugchatter.com/chat/21744/have-there-been-any-reported-adverse-effects-with-vascepa/
DrugChatter: Have there been any reported adverse effects with vascepa? Read Post »
Get new actionable insights and updates from BiotechBlog
